Take a behind the scenes look at how some of the heroic vacinnated healthcare workers found out that they were being sent to the Super Bowl.
Take a behind the scenes look at how some of the heroic vacinnated healthcare workers found out that they were being sent to the Super Bowl.
Brexit, COVID-19 and overseas competition are challenging fintech's future, and Britain should act to stay competitive for the sector, a government-backed review said on Friday. Britain's departure from the European Union has cut the sector's access to the world's biggest single market, making the UK less attractive for fintechs wanting to expand cross-border. The review headed by Ron Kalifa, former CEO of payments fintech Worldpay, sets out a "strategy and delivery model" that includes a new billion pound start-up fund and fast-tracking work visas for hiring the best talent globally.
A former client of accused Sydney conwoman Melissa Caddick has spoken out after the 49-year-old was confirmed dead on Friday.
Romania's Orthodox Church will continue immersing infants in water during baptism ceremonies, it said on Thursday, rejecting calls across the country to change the ritual after a six-week-old baby died after being baptised earlier this month. Prosecutors are investigating the case, which has divided Church officials and believers, with tens of thousands of Romanians petitioning the Church to sprinkle water on the babies' heads instead. The majority of Romania's 20 million people are Orthodox Christians and the Church has considerable influence.
Mitsubishi Corp has decided to pull out of the Vinh Tan 3 power plant in Vietnam, two sources familiar with the company's thinking on the matter told Reuters, as it shifts away from carbon intensive businesses in the face of climate change. Mitsubishi's move to exit the estimated $2-billion project shows how willing Japanese companies and financiers are to drop once-strong support for coal, under pressure from shareholders and activists. Japan's big banks regularly topped lending league tables for coal mines and power stations.
To NASDAQ Copenhagen A/S Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 26 February 2021 Company Announcement number 20/2021 Opening of new fixed-rate bonds Realkredit Danmark will open new callable fixed-rate mortgage covered bonds (SDRO) with the following characteristics: CouponSeriesAmortisationClosing dateMaturity1.50%27SAnnuity*31-08-202301-10-20531.00%22SAnnuity31-08-202301-10-2043 *) with option on up to 10 years interest only. The mortgage covered bonds will be issued in DKK from Capital Centre S. The final terms of the bond will be published by announcement of prospectus as soon as they are available. The Executive Board Any additional questions should be addressed to Chief analyst, Hella Gebhardt Rønnebæk, phone +45 45 13 20 68. Attachment Nr. 20_Aabning af ny 1% 2043 22S og 15 % 2053 27S _uk
China's Ant Group is in talks with other shareholders in its new consumer finance unit to bolster the firm's capital as it prepares to fold in its lucrative micro-lending businesses, people familiar with the matter said. Ant plans to bring the bulk of its micro-lending businesses into the unit - equivalent to roughly 1 trillion yuan ($155 billion) in outstanding loans - a move which will allow it to maintain operations nationwide and expand more easily, said two sources. The plans reflect intense regulatory pressure on Ant to rein in some of its operations and subject them to rules and capital requirements similar to those for banks.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Tryg Forsikring A/S - Settlement of Floating Rate Restricted Tier 1 Capital Notes issuance In accordance with the announcement on 24 February 2021, the issue of Tryg Forsikring A/S' Restricted Tier 1 Capital Notes for the amount of SEK 1.000m (the "Transaction") has been settled. Additional information:For further information, visit tryg.com or contact: Investor Relations Officer, Gianandrea Roberti at +45 20 18 82 67 or email@example.com Investor Relations Manager, Peter Brondt at +45 22 75 89 04 or firstname.lastname@example.org This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction pursuant to the Transaction or otherwise in any jurisdiction in which such offer, invitation or solicitation is unlawful. This announcement does not constitute a prospectus, prospectus equivalent document or an exempted document. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933 (the "US Securities Act"), as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States. About TrygTryg is one of the largest insurance companies in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for more than 4 million customers on a daily basis. Tryg is listed on NASDAQ Copenhagen and 53% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 650m to peace of mind purposes via TrygFonden. Notice to U.S. investorsThis announcement does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the US Securities Act, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements. Cautionary note about forward-looking statementsThis announcement (including any information incorporated by reference in this announcement), oral statements made regarding the Transaction, and other information published by Tryg contain statements which are, or may be deemed to be, "forward-looking statements". Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Tryg about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Forward looking statements often use words such as "believe", "expect", "estimate", "intend", "anticipate" and words of a similar meaning, and phrases or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved (or, in each case, their negative or other variations). You should not place undue reliance on these forward-looking statements, which reflect the current views of Tryg, are subject to risks and uncertainties about Tryg and are dependent on many factors, some of which are outside of Tryg's control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different. Except as required by law, Tryg undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment Tryg Forsikring AS_settlement of Restricted Tier 1 Notes issuance
African-Australian community leaders are outraged by the video that Trinity College said “wasn’t racially motivated”.
(Bloomberg) -- Global bonds attempted to recover from an aggressive selloff that drove steep losses in Treasuries and U.S. stocks Thursday. Asian shares slumped and U.S. and European futures pointed lower.Benchmark Treasury yields fell back below 1.5% after trading as high as 1.6% Thursday, when a poorly received government auction led to forced selling by holders of mortgage securities. Their Australian equivalents swung amid an unscheduled purchase operation from the country’s central bank, though a mid-session bond rally faded as the day progressed. Japan’s benchmark hovered near its highest level since early 2016. The dollar extended overnight gains.Stocks dropped more than 3% in Japan and Hong Kong, and were weaker across the region. S&P 500 futures slipped after the benchmark closed down 2.5% with tech shares leading losses. The Nasdaq 100 tumbled 3.6%, the most since October, as investors rotated into companies poised to benefit from an end to lockdowns. Still, stocks popular with the day-trader crowd surged once again, with GameStop Corp. doubling at one point before ending 19% higher.Investors are betting on a sharper-than-expected rebound for the global economy, with some growing increasingly worried that accelerating inflation could trigger a pullback in monetary policy support. Federal Reserve officials so far say surging Treasury yields reflect optimism and have stressed that the central bank has no plans to tighten policy prematurely.What Investors Are Watching After the Spike in Treasury Yields“A move of this magnitude is not healthy for markets and equities are rightfully acting negatively to it,” said Matthew Miskin, the co-chief investment strategist at John Hancock Investment Management. “We will be watching to see if the Fed pushes back more meaningfully on the recent rise in yields.”The 10-year U.S. yield adjusted for inflation rose to its highest level since June, a warning sign for riskier assets that have benefited from exceptionally loose financial conditions amid the pandemic.In remarks this week, Federal Reserve Chairman Jerome Powell offered reassurance that policy would continue to be supportive and look beyond a temporary pick-up in inflation, especially from a low base. Nevertheless, money-market traders have now almost fully priced in a first rate hike by the end of next year.Read more: Soaring U.S. Yields Send Risk Assets Warning as Real Rates RiseElsewhere, oil retreated from its the highest in more than a year as traders mulled depleting global inventories. Bitcoin traded below $50,000 again. Gold extended an overnight decline.Some key events to watch this week:Finance ministers and central bankers from the Group of 20 will meet virtually Friday. U.S. Treasury Secretary Janet Yellen will be among the attendees.These are some of the main moves in markets:StocksS&P 500 futures fell 0.4% as of 7:03 a.m. in London. The S&P 500 Index fell 2.5%.Japan’s Topix Index fell 3.2%.S&P/ASX 200 fell 2.4%.South Korea’s Kospi Index fell 2.9%.Hang Seng Index fell 3.2%.Shanghai Composite Index fell 2.1%.CurrenciesThe Bloomberg Dollar Spot Index rose 0.2% after gaining 0.6% Thursday.The euro was 0.2% lower at $1.2150.The British pound fell 0.6% to $1.3934.The Japanese yen was flat at 106.19 per dollar.The offshore yuan rose 0.2% to 6.4786 per dollar.BondsThe yield on 10-year Treasuries slipped four basis points to 1.48%.Australia’s 10-year yield was up 18 basis points at 1.92%.CommoditiesWest Texas Intermediate crude fell 1.5% to $62.60 a barrel.Gold fell 0.5% to $1,761 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Tim Hortons China has completed a new fundraising round from Sequoia Capital China, Tencent Holdings and Eastern Bell Capital, and plans to add more than 200 shops to its network this year, the coffee chain operator said on Friday. The Toronto-based firm, which competes with Starbucks Corp and Coca-Cola's Costa Coffee in China, did not disclose how much cash it had raised, but said the funds would be channeled into building more outlets as well as its digital infrastructure and brand. Tim Hortons has opened more than 150 shops in ten cities since it entered China two years ago, calling them "profitable", but domestic proprietors have complained of tough price competition.
European stock index futures fell more than 1% on Friday, tracking steep losses on Wall Street and in Asian markets as a jump in bond yields and concerns of lofty equity valuations hammered demand for riskier assets. Euro Stoxx 50 futures slumped 1.7% by 0637 GMT, while FTSE futures and DAX futures fell 1.2% and 1.4%, respectively. Asian markets fell to a one-month low, while the dollar rose from a three-year trough as the 10-year Treasury yield hit a one-year high of 1.614%, sparking fears the heavy losses could trigger distressed selling in other assets.
Goodvalley delivered solid results amid challenging 2020 While the year came off to a good start based on high live pig prices, solid volume growth and strong production efficiency, the global outbreak of COVID-19 put an abrupt end to the positive development. Demand for live pigs and pork products dropped across our markets due to reduced consumption, temporary closures of slaughterhouses and very limited export activities. The significant negative impact on demand and prices was further exacerbated by the effects of an outbreak of African Swine Fever in Germany in the second half of the year where we also saw a sharp increase in feed prices. “2020 was a year of unprecedented challenges and unusual market conditions, and we are proud to report strong operational performance and solid financial results based on our dedicated employees’ extraordinary discipline and work efforts during a difficult period,” says CEO Hans Henrik Pedersen. Highlights • Group revenue decreased by 4% to DKK 1,463 million (2019: DKK 1,526 million), and Adjusted EBITDA came to DKK 316 million (2019: DKK 274 million), corresponding to an Adjusted EBITDA margin of 21.6% (2019: 17.9%). • The Polish segment’s revenue declined to DKK 871 million (2019: DKK 925 million), and Adjusted EBITDA came to DKK 114 million (2019: DKK 112 million)corresponding to an increase in Adjusted EBITDA margin of 13.1% (2019: 12.1%), realised despite lower pig prices and a drop in the meat to feed ratio as the low pig prices were not reflected in the feed price, which was stable. • Ukrainian segment revenue came to DKK 461 million (2019: DKK 429 million), and Adjusted EBITDA increased to DKK 161 million (2019: DKK 113 million) corresponding to an Adjusted EBITDA margin of 34.8% (2019: 26.3%) driven by a significant improvement in our arable production due to a strong focus on crop rotation, despite flooding at the beginning of the year, and a significantly improved pig production efficiency which lifted the number of pigs sold per sow. • Revenue in the Russian business declined to DKK 131 million (2019: DKK 172 million) due to the lower volume and a decrease in the average sales price, and Adjusted EBITDA fell to DKK 40 million (2019: DKK 49 million) corresponding to an Adjusted EBITDA margin of 30.5% (2019: 28.5%), primarily caused by the PRRS outbreak, which impacted volumes produced throughout the year and entailed a sharp decline in the number of pigs sold per sow. OutlookIn 2021, Goodvalley expects to generate revenue of DKK 1,450 - 1,600 million and an Adjusted EBITDA of 230-280 million. The outlook is based on expectations of a relatively stable pig price level compared to the average price in 2020 and good production efficiency. The outlook for 2021 is based on an average market price for live pigs of DKK 11.30 per kilo slaughter pig (2020 reported: DKK 11.19 per kilo slaughter pig) and a feed price of DKK 1.66 per kilo (2020 reported: DKK 1.65 per kilo) in the pig division and the prevailing economic situation in Goodvalley’s markets. The outlook is furthermore based on exchange rates for the Group’s key currencies remaining at the closing rates in December 2020 for the full year. Further information Group CFO, Jakob Brasted + 45 76 52 20 00 email@example.com GOODVALLEY AT A GLANCE Goodvalley is an international producer of high-quality pork products operating in Poland, Ukraine and Russia based on Danish production standards. The company is to a large extent self-sufficient and masters the whole production chain from field to fork, from growing crops for feed, breeding and slaughtering pigs including using the manure in biogas facilities to produce electricity and organic fertilizer for the fields. Goodvalley is certified as a carbon neutral company by German TÜV and operates according to the highest standards in terms of animal welfare, transparency in the production and sustainable production methods. Attachments Goodvalley Annual Report 2020 Goodvalley Sustainability Report 2020
Raymart Santiago has become a negligent father since he started dating fellow actor Jodi Sta. Maria, said Claudine Barretto, Santiago’s estranged wife. Santiago and Sta. Maria went public with their relationship in October. A few months later, Barretto said she was displeased with the two because they had broken a promise that they had made, ... This article, Claudine Barretto says Jodi Sta. Maria is ‘not a good influence’ on her ex-husband, originally appeared on Coconuts, Asia's leading alternative media company.
Japanese shares have slumped, logging their biggest daily decline in nearly a year, after a spike in global bond yields spooked investors already uneasy about the market's stretched valuation.The Nikkei average on Friday ended down 3.
(Bloomberg) -- Bitcoin’s rally this year has hit a speed bump, putting it on track for the worst weekly slide in almost a year amid wider losses in risk assets.The largest cryptocurrency slumped as much as 21% this week, the most since March. The wider Bloomberg Galaxy Crypto Index, tracking Bitcoin, Ether and three other cryptocurrencies, is down 23% this week.The price earlier dipped to as low as $45,525, nearing a key Fibonacci level at around $45,000, before recovering some losses to about $46,375 as of 6:21 a.m. in London, according to consolidated pricing compiled by Bloomberg.The rough patch for Bitcoin comes amid wider chaos in global markets, as a surge in bond yields heralds growing expectations that growth and inflation are moving higher and forcing traders to reevaluate their positions across multiple asset classes. The tech-heavy Nasdaq 100 dropped in seven of the past eight sessions as stocks like Tesla Inc. and Peloton Interactive Inc. declined.“Risk-on assets are taking a hit at the moment -- we’re seeing stocks slide and crypto is following,” said Vijay Ayyar, head of Asia Pacific for cryptocurrency exchange Luno in Singapore. “The dollar is strengthening, which is a good indication to expect a slide in Bitcoin and crypto.”Bitcoin’s weakness in the face of market gyrations raises questions about its efficacy as a store of value and hedge against inflation, a key argument among proponents of its stunning fivefold rally over the past year. Detractors have maintained the digital asset’s surge is a speculative bubble and it’s destined for a repeat of the 2017 boom and bust.In a Flash, U.S. Yields Hit 1.6%, Wreaking Havoc Across MarketsWhile Bitcoin is often touted as the new “digital gold,” the yellow metal is winning out at the moment with spot gold holding at $1,764 per ounce, down about 1.1% for the week. The Bloomberg Dollar Spot Index is up 0.4% in the same period, on track for its strongest gain in a month.Heavy selling in the Grayscale Bitcoin Trust, the world’s largest such fund, as well as the expiry of Bitcoin options are also contributing to the volatility, Ayyar said. The trust has slumped 20% this week, with losses at one point racing past its underlying asset, as a once-massive price premium over Bitcoin has evaporated as investors cashed in on those gains, he said.Prominent figures across the financial world have also recently weighed in on Bitcoin.Tesla chief executive Elon Musk said the prices “seem high” on the weekend, seen by some as an initial catalyst for the week’s selloff. Ark Investment Management’s Cathie Wood later said in a Bloomberg interview she was “very positive on Bitcoin” but didn’t disclose whether Ark had made a purchase.Earlier this week, Microsoft Corp. co-founder Bill Gates said in a Bloomberg Television interview he wasn’t a fan of Bitcoin, while Treasury Secretary Janet Yellen said the token was an “extremely inefficient way of conducting transactions.”(Updates pricing, additional analysis.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Solskjaer ‘not sure’ on Edinson Cavani, Donny van de Beek and Scott McTominay fitness
CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. Following the announcement, the Company will host a live teleconference and webcast at 2:00 p.m. GMT (9:00 a.m. EST) that same day (details below). To access the webcast, please use the following link: https://edge.media-server.com/mmc/p/zejeosdn To participate in the call, please find details below: Date:Monday, March 8, 2021Time:0900 EST / 1400 GMTDial-in:United Kingdom +44 (0) 800 694 1461(Toll Free) / +44 (0) 844 493 6766 (Local)United States +1 866 280 1157 (Toll Free) / +1 646 787 1226 (Local)All other locations +44 (0) 203 009 5709Conference ID:7268122 The press release and the live audio webcast will also be available in the investor section of Abcam’s corporate website at corporate.abcam.com/investors/reports-presentations/. An archive will be available after the call at that same address. For further information, please contact: Abcam James Staveley, VP Investor Relationsjames.firstname.lastname@example.org + 44 (0) 1223 696 000 Numis - Nominated Adviser & Joint Corporate BrokerGarry Levin / Duncan Monteith / Huw Jeremy+ 44 (0) 20 7260 1000 About Abcam plcAs an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways. Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results. Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM). For more information, please visit www.abcam.com or www.abcamplc.com Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding Abcam’s expectation of reporting Interim Results and holding the related teleconference on March 08, 2021, Abcam's portfolio and ambitions, expected performance for first half 2021, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus (“COVID-19”), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption “Risk Factors” in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 at 7 p.m. local time across the United States and on the Bloomberg Network in Europe on Sunday, February 28, 2021 at 6 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes and on the Bloomberg Network in Europe in 100M homes at 6 p.m. local time on Sundays. In the exclusive interview, Dr Shailubhai discusses topline data from Tiziana’s COVID-19 trial, its multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases. “The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. About Tiziana Life Sciences Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. For further enquiries: United Kingdom Investors: Tiziana Life Sciences plc (TLSA) Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 U.S. Investor Relations Contact: RedChip Companies, Inc.Dave Gentry407email@example.com
As a result of the ongoing global virus crisis, the revenue, adjusted EBITDA and profit of AS Tallinna Sadam (hereafter: “the Group”) decreased in Q4. Revenue amounted to EUR 25.3 million decreasing by 15.7% in Q4 year-on-year. The adjusted EBITDA of Q4 was EUR 12.1 million (–18.3%) and the profit amounted to EUR 5.7 million (–32.3%). In 2020, the annual revenue was EUR 107.4 million (–17.8%) and adjusted EBITDA amounted to EUR 58.4 million (–21.4%). Despite the pandemic, the profit for 2020 was EUR 28.5 million (–35.8%). Adjusted EBITDA margin decreased by 2.5 percentage points, but the volume of investments increased to EUR 37.1 million (+26%). According to Valdo Kalm, Chairman of the Management Board of Tallinna Sadam, the negative impact of the pandemic on the company's financial results was particularly noticeable in the Passenger harnours segment, but the overall impact of the virus on the Group's finances was smaller than feared and the year ended with a strong profit given the circumstances. „The year 2020 proved that the business strategy with diversified risks and the contribution to the four business directions is justified. In a situation where the business related to passengers decreased by almost half, we are able to meet the expectations of investors and continue with the promised dividend policy, i.e. pay at least 70% of the previous year's profit for dividends," explained Kalm. Kalm says that the large drop in the number of passengers has been compensated by the highest cargo volume of the last five years, the sales revenue of passenger ferries and icebreaker Botnica, which have all remained at levels comparable to 2019. “The resulting stable cash flow and confidence in the recovery of the passenger business have also enabled us to continue investing in passenger services and infrastructure despite the crisis, especially in the Old City Harbour, where we have introduced innovative environmentally friendly solutions such as automatic mooring and on-shore power supply. This year, despite the slump in the passenger segment, several passenger service and real estate development projects in the Old City Harbour will be completed or continued, including the cruise terminal, the front square of the Terminal D and the pedestrian bridge of the Admiralty Canal,” added Kalm. Please also see Valdo Kalm’s video message. The management of Tallinna Sadam will present the financial results of the Group at a webinar on 26 February at 11:00, to attend, please click here. The webinar will be held in English. Key figures (in million EUR): Q4 Q4 +/– 2020 2019 +/– 2020 2019 % % Revenue 25.3 30.0 –15.7 107.4 130.5 –17.8 Adjusted EBITDA 12.1 14.8 –18.3 58.4 74.3 –21.4 Adjusted EBITDA margin 47.9% 49.5% –1.6 54.4% 56.9% –2.5 Operating profit 6.3 9.1 –31.1 35.6 51.7 –31.2 Income tax 0.0 0.0 – –4.9 –5.8 –14.8 Profit for the period 5.7 8.5 –32.3 28.5 44.4 –35.8 Investments 8.2 10.7 –23.0 37.1 29.5 26.0 31.12.2020 31.12.2019 +/– Total assets 628.1 625.5 0.4% Interest bearing debt 211.6 207.8 1.8% Other liabilities 41.1 40.7 1.0% Equity 375.4 377.0 –0.4% Number of shares 263.0 263.0 0.0% Major events in Q4: The impact of the COVID-19 pandemic continuedCompromise with ESTEVE to end legal disputesAppointment of Indrek Randveer as chairman of the Management Board of TS Laevad OÜEnlight Research started covering Tallinna SadamThe supervisory board approved the company strategy for 2021–2025The results of the mapping of the ecological footprint of Tallinna SadamAndo Leppiman was elected chairman of the Tallinna Sadam nomination committeeCompletion of the parking structure of passenger terminal DPast five years’ record cargo volume in 2020 – 21.3 million tons RevenueRevenue for Q4 of 2020 decreased by EUR 4.7 million, i.e. 15.7%, year on year mainly due to decline in passenger volumes. Annually, the revenue decreased in total by 17.8% to EUR 107.4 million. Revenue decreased in all revenue streams, the sharpest in passenger fees (–59%) and vessel dues (–20%). The decline is mainly attributable to the cancellation of the cruise season as well as reduced ferry timetables and a slight decrease in the volumes of general, dry bulk and container cargo. Growth in the volume of liquid bulk cargo had a positive effect on revenue.The revenue of the Passenger harbours segment decreased because the number of passengers declined in connection with COVID-19 related mobility restrictions, which led to the reduction of ferry timetables and the cancellation of the cruise season. The fourth quarter revenue of the Passenger harbours segment decreased to EUR 6.2 million (–41%)Q4 revenue of the Cargo harbours segment grew by EUR 0.2 million (+2.1%) to EUR 10.6 million. Annually, the revenue of the Cargo harbours segment decreased only slightly because cargo throughput grew by 7%. Cargo volume increased primarily due to liquid bulk, but the increase in the volume of liquid bulk with lower charge did not cover the effect of the decrease in the volume of other types of cargo in total cargo charge revenue.The revenue of the Ferry segment decreased mostly during the summer season when the customer (the state) ordered a smaller number of extra trips and did not order an additional ferry to be put in service. Fourth quarter revenue decreased to EUR 6.9 million (–1.7%).The revenue of the segment Other decreased both in Q4 and annually, because of the shorter summer charter period of the icebreaker Botnica due to COVID-19 related restrictions, which disrupted the production operations of the Canadian charterer. The indexation of the ice-breaking and charter fee rates to the inflation index had a slight positive effect on revenue. Revenue for the fourth quarter decreased to EUR 1.6 million (–27%). EBITDAAdjusted EBITDA for Q4 declined by EUR 2.7 million (–18.3%) year on year. The annual adjusted EBITDA decreased to EUR 58.4 million (–21.4%) due to a fall in the Passenger harbours segment. Adjusted EBITDA margin declined from 56.9% to 54.4%. ProfitThe Group’s net profit for 2020 amounted to EUR 28.5 million, EUR 15.9 million less than a year earlier. Net profit for Q4 was EUR 5.7 million (–32.3%). Profit before tax decreased by EUR 16.7 million to EUR 33.4 million (–33.4%) in 2020. Profit before tax for the fourth quarter decreased by EUR 2.7 million, year on year. Income tax expense decreased by EUR 0.9 million due to a smaller dividend distribution (EUR 30.2 million) compared with dividend paid in 2019 (EUR 35.2 million). InvestmentsQ4 capital investments amounted to EUR 8.2 million, capital investments in 2020 totalled EUR 37.1 million, which is 26% more than in the prior year and the past few years’ highest figure. The main investments were again made at the Old City Harbour, where despite the crisis the Group continued to invest in major improvements to the environment and travel conditions. The largest completed projects were the reconstruction of Terminal D and the construction of a nearby multi-storey parking structure. The installation of on-shore power supply systems and auto-mooring equipment for ferries reached the final phase and the construction of a cruise terminal and a footbridge across the canal of the Admiralty Basin was started. The largest works at the Muuga Harbour were related to improving the conditions of ro-ro traffic. Dredging works were carried out in the turning basin and approach canal of the Paldiski South Harbour. The largest projects in the Ferry segment were the installation of battery bank energy solution on the ferry Tõll in order to achieve energy savings and make the ferry more environmentally friendly and scheduled smaller-scale dry dock maintenance of ferries. On the icebreaker Botnica, the second part of the machinery control system was renewed and other technical systems were also upgraded. Interim condensed consolidated statement of financial position: In thousands of euros 31 December 2020 31 December 2019 ASSETS Current assets Cash and cash equivalents 26,679 35,183 Trade and other receivables 10,183 10,614 Inventories 360 408 Non-current assets held for sale 114 142 Total current assets 37,336 46,347 Non-current assets Investments in associates 1,147 1,609 Other long-term receivables 0 294 Property, plant and equipment 587,506 575,267 Intangible assets 2,104 2,015 Total non-current assets 590,757 579,185 Total assets 628,093 625,532 LIABILITIES Current liabilities Loans and borrowings 17,266 16,266 Derivative financial instruments 102 243 Provisions 1,289 1,915 Government grants 1,919 193 Taxes payable 744 893 Trade and other payables 9,149 11,755 Total current liabilities 30,469 31,265 Non-current liabilities Loans and borrowings 194,314 191,580 Government grants 26,145 24,754 Other payables 1,733 915 Total non-current liabilities 222,192 217,249 Total liabilities 252,661 248,514 EQUITY Share capital at par value 263,000 263,000 Share premium 44,478 44,478 Statutory capital reserve 20,262 18,520 Hedge reserve –102 –243 Retained earnings (prior periods) 19,276 6,859 Profit for the period 28,518 44,404 Total equity 375,432 377,018 Total liabilities and equity 628,093 625,532 Interim condensed consolidated statement of profit or loss: In thousands of euros Q4 2020 Q4 2019 2020 2019 Revenue 25,303 30,005 107,358 130,536 Other income 223 229 3,015 1,017 Operating expenses –7,576 –9,212 –30,858 –36,669 Personnel expenses –5,426 –5,740 –19,491 –19,867 Depreciation, amortisation and impairment –6,199 –6,125 –24,094 –23,037 Other expenses –68 –77 –368 –301 Operating profit 6,257 9,080 35,562 51,679 Finance income and costs Finance income 7 13 36 42 Finance costs –410 –463 –1,705 –1,797 Finance costs – net –403 –450 –1,669 –1,755 Share of profit of an associate accounted for under the equity method –130 –173 –462 244 Profit before income tax 5,724 8,457 33,431 50,168 Income tax 0 0 –4,913 –5,764 Profit for the period 5,724 8,457 28,518 44,404 Attributable to owners of the Parent 5,724 8,457 28,518 44,404 Basic and diluted earnings per share (in euros) 0.02 0.03 0.11 0.17 Basic and diluted earnings per share – continuing operations (in euros) 0.02 0.03 0.11 0.17 Interim condensed consolidated statement of cash flows: In thousands of euros 2020 2019 Cash receipts from sale of goods and services 114,378 138,690 Cash receipts related to other income 94 193 Payments to suppliers –43,954 –47,210 Payments to and on behalf of employees –15,713 –16 892 Payments for other expenses –376 –377 Income tax paid on dividends –4,913 –10,985 Cash from operating activities 49,516 63,419 Purchases of property, plant and equipment –35,811 –27,965 Purchases of intangible assets –661 –550 Proceeds from sale of property, plant and equipment 2,863 39 Government grants received 3,561 0 Dividends received 0 204 Interest received 15 28 Cash used in investing activities –30,033 –28,244 Redemption of debt securities –9,000 –9,000 Loans received 20,000 10,000 Repayments of loans received –7,266 –6,766 Dividends paid –30,008 –34,970 Interest paid –1,694 –1,769 Other payments related to financing activities –19 –50 Cash from/used in financing activities –27,987 –42,555 NET CASH FLOW –8,504 –7,380 Cash and cash equivalents at beginning of the period 35,183 42,563 Change in cash and cash equivalents –8,504 –7,380 Cash and cash equivalents at end of the period 26,679 35,183 Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region, which serves annually 10 million passengers and 20 million tons of cargo in average. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and construction services in Estonia and offshore projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services. According to unaudited financial results, the group’s sales in 2020 totalled EUR 107.4 million, adjusted EBITDA EUR 58.4 million and profit EUR 28.5 million. Additional information: Marju ZirelHead of Investor RelationsTel. +372 5342 6591E-mail: firstname.lastname@example.org Attachments Tallinna Sadam results 12M 2020 ENG Tallinna Sadam Q4 2020 results presentation ENG Tallinna Sadam Financial Results Q4 and 12M 2020 Data
Company announcement, Helsinki, 26 February 2021 at 9:00 am (EET) NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2020 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), today provides its financial statements for the full year 2020 (1 January–31 December 2020) and H2 2020 (1 July-31 December 2020). Highlights, July – December 2020 Continued to minimize the effect of COVID-19 pandemic as well as focusing on generating profitable revenue growth. Considering the difficult business environment, excellent progress with 9 new NBS systems sold, 3 in the US 6 in the EU and rest of the world. Total of 3 new NBT® systems installed to clinics in the US and Europe, across multiple sites, for the treatment of Major Depressive Disorder (MDD) July 1 – December 31, 2020 was the Company’s best reported second half to date when measured by net sales and operating result. The total net sales in the second half was EUR 2.5 million (2019 H2: EUR 2.1 million) and operating result EUR -1.5 million (2019 H2: -3.2 million) NBS net sales grew by 4% in H2 to EUR 1.3 million (2019 H2: EUR 1.2 million) and the NBT net sales grew by 35% in H2 amounting to EUR 1.2 million (2019 H2: EUR 0.9 million) Started two new pilot studies in treating severe depression (Kuopio University Hospital) and therapy resistant, chronic neuropathic pain patients (Helsinki University Hospital) with accelerated iTBS therapy treatment protocols using NBT system. Post-period Highlights Shareholders were invited to the Extraordinary General Meeting (EGM) of the Company to decide on authorizations for the Board of Directors to decide on share issues and issuances of option rights and special rights to shares. The EGM will be held on Monday, March 1, 2021 Business Overview Nexstim is a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. The Company developed its NBT® device based on its NBS technology platform; commercialisation of the NBT® system is currently Nexstim’s key strategic focus. NBT® Nexstim’s NBT® platform is based on its unique navigated Transcranial Magnetic Stimulation (nTMS) technology which allows for personalized, accurate, reproducible and non-invasive brain stimulation In May 2018, Nexstim launched its Navigated Brain Therapy (NBT®) system in the US for the treatment of MDD following FDA clearance in November 201 MDD affects more than 300 million people worldwide with 20-40% of patients not responding to current treatment options. As a result, MDD is the key focus for Nexstim’s sales and marketing activities for its NBT® system The NBT® system is CE marked for the treatment of depression and chronic pain Two ongoing pilot studies in treating severe depression and therapy resistant, chronic neuropathic pain patients with accelerated iTBS therapy treatment protocols Active commercial installed base of 31 therapy treatment systems across three continents NBS Nexstim’s NBS system is the only CE-marked and FDA-cleared non-invasive solution for pre-surgical mapping of the motor cortex in brain cancer. Clinical data has been generated demonstrating the value of Nexstim’s unique navigation system for pre-surgical mapping with regard to patient outcomes The NBS system allows surgeons to be better prepared and more aggressive with tumor resection, due to their confidence in the location of the motor and speech cortex because of pre-surgical mapping. The non-invasive device has demonstrated a 46% increase in progression free survival in low grade gliomas versus the current gold standard The NBS system has been sold to approximately 180 research universities and leading hospitals across the world CEO Mikko Karvinen’s review Year 2020 has been a time for Nexstim to adjust and learn a new way of doing business under the global health and financial crisis caused by the COVID-19 pandemic. At first, we faced the crisis by safeguarding our valuable cash resources in the form of executing necessary adjustments needed and quick implementation of a savings program. We continued by ensuring that the vast number of both NBS and NBT® customers could continue to operate their systems in a very difficult business environment. Also new ways of digital sales and marketing were successfully implemented to continue our growth path for the full year 2020. I am proud of our Nexstim teamwork under these extreme conditions, and as a sign of our success we achieved the best year so far measured by several financial metrics, including record revenue level. Fortunately, as we have significantly improved the Company's financial performance, we have also continued to safeguard the well-being of our personnel and doing our best in ensuring that our personnel and family members stay as safe as possible. This has been the first year of implementing our newly renewed strategy for the years 2020-2024. Nexstim continues to enable personalised and effective therapies and diagnostics for challenging brain diseases and disorders. Our main strategic focus will stay in the therapeutic indications where we will bring the new accelerated therapy protocols to the core development path of our business. We see that this is possibly a game changer in the field of TMS treatments as we will seek for validation of higher efficacy rates and to show the benefits of a faster treatment process through our pilot studies. The selected therapeutic applications (MDD, severe depression and chronic pain) represent indications where our unique technology already demonstrates recognisable clinical outcome and customer profitability and where possibly in more severe cases also more hospital inpatient treatments are required in the future. We will progress in our science-based development path so that Nexstim’s navigated TMS device will continue to be at the forefront of delivering new treatments for future indications. The NBS business was a significant source of income for our Company in the full year 2020, with net sales growing by 19% to EUR 2.2 million (2019: EUR 1.8 million). The systems were sold especially well in the United States, where, despite the COVID-19 environment, 6 new NBS Systems were successfully sold and delivered during the year 2020. As a result, the Company's total net sales increased by 23 percent during the full year of 2020 to new record level of EUR 4.1 million (2019: EUR 3.3 million). We also ensured the continuity of the NBS service business despite the difficult customer environment and we did not lose any service contract customers as hospital neurosurgeries continued almost unchanged despite the health crisis. During 2021, we will continue to invest in the growth of the NBS business, for example, with recruitment of new sales team members to our US organization. During full year 2020, the NBT business suffered a bit more from the effects of the COVID-19 pandemic. NBT client clinics and hospitals had to somewhat limit therapy treatments locally due to lockdown measures and mobility restrictions, and this slowed down the number of systems and services sold as well as disposable parts delivered, especially to U.S. therapy clinics. We also had to drastically reduce our commercial personnel in our subsidiaries due to the cost saving program, especially in NBT sales, as the short-term effects of the measures taken were necessary to secure our cash balance. Despite these negative effects, the net sales of the NBT business increased by 28 percent during full year 2020 and amounted to EUR 2.0 million (2019: EUR 1.5 million). During full year 2020, we delivered and installed a total of 8 new NBT® Systems - 6 to the U.S. and 2 to Europe and the rest of the world for use in the treatment of MDD. As a result, there were at the end of 2020 a total of 31 NBT® Systems installed worldwide (16 in the U.S. and 15 in Europe and the rest of the world) for the treatment of depression and chronic neuropathic pain. We are confident that by further emphasising the unique navigation capabilities of the NBT® System, we can increase our market share. This is accomplished by clearly differentiating our system from the TMS systems currently on the market that do not have navigation capabilities. In the future, the need for a navigation function is likely to be further emphasised in technology that could treat patients in hospital for severe, treatment-resistant depression (TRD) and possible suicidal ideation. This could potentially open a new TMS treatment market for Nexstim that is separate from the current treatment of patients with MDD. To better understand the ability of Nexstim’s NBT® System to treat patients with accelerated treatment protocols, we launched two new pilot trials in Finland during H2 2020, one for severe depression at Kuopio University Hospital and another for therapy resistant chronic neuropathic pain at Helsinki University Hospital. We are awaiting first results from the severe depression pilot trial soon. As a company, Nexstim wants to be a pioneer in researching and commercialising this new treatment method that could potentially shake the whole TMS industry. In addition to the commercial advancement of NBT® Systems, we also saw continued development in sales, driven by high-margin aftersales products, including revenue from services, support functions, spare parts, and disposables. As the share of NBT® business from the total revenue increases, the share of recurring revenue is likely to increase. Recurring revenue (total sales of the therapy business excluding NBT® System sales) during full year 2020 covered 86 percent of the therapy business revenue. During the full year 2020, Nexstim achieved an average of EUR 71 thousand in therapy revenue per NBT® System. Nexstim's cash and cash equivalents on December 30, 2020 totalled EUR 3.5 million, including the Kreos loan. During full year 2020, we succeeded in reducing the negative cash flow from operating activities to EUR -2.7 million, compared to EUR -6.7 million in 2019, especially through austerity measures and increased gross margin. The Company loans decreased in April 2020 as innovation funding agency Business Finland decided that a total of EUR 0.9 million from the capital and interest of three loans granted for Nexstim’s research and development projects has been settled by debt cancellation. To further finance our business and growth strategy, we raised a total of EUR 2.2 million in new capital in the spring 2020 rights issue. In terms of operational business, 2021 will be our first full year of executing our renewed strategy. This is a year of focused investments into accelerating our sales growth while continuing to focus on securing the service business of our existing NBS and NBT customer base and increasing the utilisation rate of our current installed base. Parallel to all growth measures we will actively keep monitoring the COVID-19 pandemic environment. We also continue our work to increase the number of NBT® Systems installed for use in the treatment of MDD, and we are doing this in line with our renewed strategy, primarily together with valued partners. The focus is particularly on the large U.S. market, but also in a targeted manor in the EU. At the same time, our goal is to continue to raise awareness of our NBT® System in the market. We aim to do this by increasing the number of patients with MDD treated with NBT® systems. As the number of patients increases and research data on pilot trials of new accelerated treatment protocols accumulate, we will be able to gather more clinical data to demonstrate the usefulness of our unique equipment to numerous depressed patients. This information is used to support our marketing and we believe it will increase the rollout of NBT® Systems in key markets in the U.S. and the EU. There are also plans to continue to leverage our strong network of leading KOL’s and patient registry treatment data. In October 2020 we reported the clinical outcomes of the first 108 patients who had completed NBT therapy for treatment of MDD at clinical sites in the U.S. About 42% of the patients completing the treatment achieved clinical remission and 74% obtained a clinical response at the end of treatment. We will continue to collect this valuable patient registry data aiming to collect a patient data registry of over 200 completed treatment sessions of depression patients during year 2021. We also plan to use this patient registry data to publish a series of background papers highlighting the benefits of our NBT® system in the treatment of major depression. Despite we still live in the prolonged COVID-19 pandemic, we eagerly look forward to the year 2021 as the first full year of executing our new strategy. I know that our Nexstim team will work hard to increase shareholder value over the long-term in the form of stronger competitive advantages, faster growth, and better financial results. While again being optimistic about the future, we will closely continue to monitor the development of the COVID-19 pandemic as we operate our business. Key performance indicators EUR in thousands7-12/20206 months7-12/20196 months1-12/202012 months1-12/201912 monthsNet sales2,499.52,130.74,114.03,348.1Personnel expenses-2,134.2-2,634.0-3,731.5-4,713.0Other operating expenses-1,065.6-1,679.3-2,429.3-3,647.5Depreciation and amortisation-177.7-319.3-366.9-524.6Operating profit (loss)-1,496.2-3,155.5-3,332.7-6,517.5Profit/ -Loss for the period-2,952.5-3,117.8-4,121.6-6,782.6Earnings per share (EUR)-0.01-0.07-0.02-0.25Cash flows from operating activities-1,164.1-3,002.5-2,724.7-6,681.5Cash in hand and at banks3,455.84,266.23,455.84,266.2Total equity-1,469.1-740.1-1,469.1-740.1Equity ratio (%)-28.25-8.49-28.25-8.49Number of shares in the end of the period (pcs)436,622,756 62,789,630 436,622,756 62,786,630 Average number of shares during the period (pcs)439,622,756 42,146,358267,693,026 27,611,274 Diluted number of shares in the end of the period (pcs)478,834,792 64,080,578478,834,792 64,080,578 Diluted average number of shares during the period (pcs)479,482,049 54,664,246290,420,292 36,392,323 Future Outlook Based on its business forecast, the Company expects its revenue to continue to grow during year 2021 and a loss for the period is expected for the financial year. Board of Directors’ Proposal on the Dividend Since it was founded, the Company's operations have been unprofitable, and no dividend has been distributed. In the forthcoming years, the Company will focus on financing the growth and the development of its business and the Company will adhere to a very stringent dividend policy, tied to the Company's results and financial standing. The Company does not expect to be able to distribute dividends in the near future. In the event dividends are distributed, all Shares will be entitled to equal dividends.At the end of the financial period of 2020, the distributable assets of the group’s parent company were EUR 12,353,405.03. The Board of Directors proposes that Nexstim Plc should not pay any dividend for the financial period of 2020. Helsinki 26 February 2021 Nexstim PlcBoard of Directors Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 email@example.com Erik Penser Bank AB (certified adviser)+46 8 463 83 firstname.lastname@example.org Publication of financial information during year 2021 The company will hold two live webinars for media, investors and analysts on Friday 26 February 2021. Mikko Karvinen CEO, and Joonas Juokslahti CFO, will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish and it takes place at 1 pm EET. The second live webinar will be in English at 3 pm EET. Webinar details: To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail. Live Webinar in Finnish on 26 February 2021 at 1 pm (EET): Register here >>> Live Webinar in English on 26 February 2021 at 3 pm (EET): Register here >>> Half-Yearly Report January-June 2021 (H1) will be published on Friday, August 13, 2021 Nexstim Annual Report 2020 (Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report) will be published on company web pages on Friday, March 5, 2020. The Annual General Meeting is tentatively scheduled to be held on Tuesday, April 29, 2020. About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information please visit www.nexstim.com Attachments Nexstim Plc Financial Statement Release 2020 EN_FINAL Auditors report 2020 Nexstim Oyj _EN 25.2.2021